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ABSTRACT
Picropodophyllin (PPP) is an anticancer drug undergoing clinical development in 
NSCLC. PPP has been shown to suppress IGF-1R signaling and to induce a G2/M cell 
cycle phase arrest but the exact mechanisms remain to be elucidated.
The present study identified an IGF-1-independent mechanism of PPP leading to 
pro-metaphase arrest. The mitotic block was induced in human cancer cell lines and 
in an A549 xenograft mouse but did not occur in normal hepatocytes/mouse tissues.
Cell cycle arrest by PPP occurred in vitro and in vivo accompanied by prominent 
CDK1 activation, and was IGF-1R-independent since it occurred also in IGF-1R-
depleted and null cells. The tumor cells were not arrested in G2/M but in mitosis. 
Centrosome separation was prevented during mitotic entry, resulting in a monopolar 
mitotic spindle with subsequent prometaphase-arrest, independent of Plk1/Aurora A 
or Eg5, and leading to cell features of mitotic catastrophe. PPP also increased soluble 
tubulin and decreased spindle-associated tubulin within minutes, indicating that it 
interfered with microtubule dynamics. 
These results provide a novel IGF-1R-independent mechanism of antitumor 
effects of PPP.
INTRODUCTION
The insulin-like growth factor-1 receptor (IGF-
1R) signaling pathway has been suggested as a target for 
cancer therapy based on studies showing that the (IGF-
1R) is important for cancer cell growth and survival, and 
is often overexpressed in malignant [1] and premalignant 
tissues [2]. Inhibition of tumor growth in vivo has been 
achieved with anti-IGF-1R antibodies, anti-ligand 
antibodies, receptor-specific tyrosine kinase inhibitors, 
and agents such as the cyclolignan picropodophyllin (PPP) 
[1]. However, compared to PPP [3-7] treatment with anti-
IGF-1R antibodies exhibited relatively weak anti-tumor 
effects in preclinical models [8, 9], and have yielded 
disappointing clinical data [1, 10]. Thus, raising the 
question whether PPP has other targets. PPP is presently 
undergoing clinical development in non-small cell lung 
cancer (NSCLC) and in glioblastoma. Tumor response 
was indicated in NSCLC patients included in the first 
clinical study, despite PPP given as third or fourth line 
treatment [11, 12]. 
Although the exact mechanism has not been 
established, PPP has been shown to suppress signaling in 
the IGF-1R pathway, reflected in enhanced degradation 
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of the receptor and reduction of phosphorylated IGF-
1R, as well as reduction of phosphorylated down-stream 
signaling proteins [3, 6, 13-19]. Treatment with PPP has 
been shown to induce apoptosis [3, 14, 15, 19-21], reduced 
cell motility [6, 18], and to inhibit tumor growth in 
xenografted mice [3, 13, 21] and in mouse tumor models 
[4, 5, 7]. Another characteristic outcome of treatment 
with PPP is the accumulation of tumor cells in the G2/M 
phase of the cell cycle [14, 17, 19, 20]. Interestingly, this 
distinguishes PPP from other molecules directly targeting 
the IGF-1R. 
One of the key regulators of the G2/M phase 
transition, M-phase progression [22, 23] as well as 
apoptosis [24, 25] is Cyclin-dependent kinase 1 (CDK1) 
in complex with cyclin B1. The CDK1/cyclin B1 complex 
also phosphorylates and activates enzymes regulating the 
mitosis-specific microtubule reorganization [26-29]. It was 
therefore hypothesized that the activity of this complex is 
affected directly or indirectly by PPP. Using the distinctive 
PPP-induced G2/M-accumulation as a starting-point, the 
aim of this study was to further investigate the antitumor 
mechanism of action of this compound. We identified a 
novel, IGF-1R-independent mechanism involving an early 
and sustained mitotic arrest associated with pronounced 
activation of CDK1 in vitro and in vivo. Depending on the 
duration of mitotic delay, some tumor cells showed signs 
of mitotic catastrophe.
RESULTS
PPP reduced viability and induced G2/M arrest in 
cancer cell lines independent of IGF-1R 
Treatment of HCC cell lines expressing different 
levels of IGF-1R with PPP reduced the percentage of 
viable cells in a dose-dependent manner (Fig. S1). These 
Figure 1: PPP induced accumulation of cancer cells in the G2/M phase. A representative experiment shows cell cycle analysis 
using PI staining followed by flow cytometry of indicated cancer cell lines (yellow) and normal human hepatocytes, or R(+) and R(-) MEFs 
(red) after treatment with vehicle (control) or with PPP (0.5 μM) for 24 h (n=3) (A). The percentages of HepG2, Hep3B and Huh7 cells 
accumulated in G2/M phase of the cell cycle at different time points after treatment with 0.5 µM PPP are shown in (B). Results show mean 
± SD, n=3, and considered significant (*) at p ≤ 0.05. FACS analysis of tumor (polyploid cells) and diploid cells (probably representing 
stromal cells) obtained from nu/nu Balb/c mice with established A549 xenografts, treated with either vehicle (left panel) or PPP (right 
panel) for 27 h (C). FACS analysis of murine lung tissue obtained from the same mice treated with either vehicle (left panel) or PPP (right 
panel) for 27 h (D). Staining of nuclei by DAPI was followed by flow cytometric analysis of cell cycle phase distribution showing G1 and 
G2/M peaks (yellow) for polyploid tumors and (red) for the diploid normal cells, S-phase is the hatched area between G1 and G2/M peaks 
(C, D). Data represent mean ± SD, n=3 (C), and n=4 (D). nHeps: normal hepatocytes, PI: Propidium iodide, PPP: picropodophyllin, R(+) 
MEFs: mouse embryonic fibroblasts overexpressing the IGF-1R, R(-) MEFs: mouse embryonic fibroblasts deficient for IGF-1R. 
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results were confirmed using the trypan blue exclusion 
assay. Since one of our goals was to investigate the 
mechanism of PPP action from a cell cycle point of view, 
we determined the lowest concentration (0.5 µM) that 
induced pronounced reduction of cell growth without 
massive cell death, and used this concentration for further 
experiments in this study. Analysis by flow cytometry 
showed that 24 h treatment with PPP induced G2/M phase 
accumulation in HCC, A549 and R+MEF (igf1r-/- cells 
overexpressing human IGFIR) cell lines, while normal 
human hepatocytes (nHeps) were not affected (Fig. 1A). 
The igf1r-/- (R-MEFs), although being deficient for the 
IGF-1R, also showed G2/M-accumulation in response 
to PPP (Fig. 1A). Kinetic studies demonstrated that the 
fraction of cells in the G2/M-phase increased already at 4 
h and peaked between 16 and 24 h (Fig. 1B). The slight 
differences in response between cell lines probably reflect 
differences in doubling time. Similarly, data was obtained 
in the ex vivo analysis of A549 xenografts. PPP induced 
a 1.5 to 3-fold increase of tumor cells in the G2/M phase, 
whereas no G2/M-accumulation was observed in the 
normal lung tissue (Fig. 1C and D). 
CDK1 activity was upregulated in cancer cells 
both in vitro and in vivo after PPP treatment
Since G2/M transition and M phase progression is 
driven by CDK1/Cyclin B, we assessed whether the PPP 
–induced G2/M accumulation was caused by alterations in 
CDK1 activity. PPP treatment was associated with CDK1 
activation in all tumor cell lines (Fig. 2A, B, C) and in the 
A549 xenografts (Fig. 2D), whereas no CDK1 activation 
was detected in normal human hepatocytes or in normal 
lung tissue (Fig. 2C, D). CDK1 activation was evident 
in HepG2 cells as early as 2 h after PPP addition and 
persisted until 48 h. Quantitative analysis demonstrated a 
2.2-fold elevation of CDK1 activity at 4 h, increasing to 
21-fold at 8 h (Fig. 2A, B) 
PPP-mediated CDK1 activation was associated 
with an early increase in Cyclin B1 and CDK1pT161 
Potential direct effects of PPP on CDK1 were 
analyzed in cell-free kinase assays, indicating no effects 
on CDK1/Cyclin A, CDK1/Cyclin E and CDK1/Cyclin B1 
(data not shown). The protein levels and phosphorylation 
of CDK1 and its regulators following PPP treatment 
were studied using Western blot (Fig. 3). In comparison 
to control, treatment of HepG2 cells with PPP increased 
Cyclin B1 protein level 2.8-fold at 8 h (Fig. 3A, D), 
correlating with an increase in transcription (Fig. 3E). 
After 24 h the level of Cyclin B1 in PPP treated cells was 
similar to the control, and not detectable at 72 h (Fig. 3A, 
B, D). Similarly, the PPP-induced CDK1activity also 
returned to the control (untreated) levels at 72 h (Fig. 2 
A,B). In addition, the amount of Cyclin B1 complexed 
with CDK1 increased in response to PPP (Fig. 3C). The 
activating phosphorylation CDK1pT161 followed the same 
pattern as Cyclin B1 protein level/CDK1 activation, with 
a corresponding decrease in the inhibitory phosphorylation 
Figure 2: PPP induced early upregulation of CDK1 kinase activity. CDK1 was immunoprecipitated using an anti-CDK1 antibody 
conjugated to agarose beads and the kinase activity was detected using histone H1 as substrate. HepG2 cells were treated with 0.5 µM PPP 
and samples taken at indicated time points (A). Quantitative analysis of the bands in (A) using image J. The red line represents CDK1 kinase 
activity of PPP-treated cells relative to control (DMSO) (black). Data represent mean ± SD of three experiments and considered significant 
(*) at p ≤ 0.05. (B). CDK1 kinase activity is upregulated in other cancer cell lines but not in normal hepatocytes after treatment with 0.5 
µM PPP (C). CDK1 kinase activity in tumor and lung tissues obtained from A549 xenograft mice treated with vehicle or with PPP for 27 h 
(D). PPP: picropodophyllin, nHep: normal hepatocytes. 
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CDK1pY15 (Fig. 3A, D). Similar results were obtained in 
the A549 cell line, but with slightly different kinetics. 
Cyclin B1 could not be detected in the tumor tissue of the 
PPP-treated A549 xenografts (Fig. S2).
PPP induced apoptosis in cancer cell lines
PPP was previously reported to induce apoptosis and 
CDK1 is known to regulate apoptosis. In the present study 
PPP induced 2.5 to 3-fold increase in apoptosis compared 
to controls (statistically significant only in HepG2 and 
MCF-7 cells) (Fig. S3A, B) with reduced levels of Mcl-1 
(Fig. S3C, D). In addition, PARP cleavage was observed 
in MCF-7 cells after 48 h of PPP treatment (Fig. S3D). To 
investigate whether these alterations were due to CDK1 
activity we depleted CDK1 using specific siRNA in MCF-
7 cells. Depletion of CDK1 (by 80-90 %) resulted in 
reduced Mcl-1 levels and PARP and Caspase3 cleavage, 
regardless of PPP treatment (Fig. S3D).
PPP induced mitotic arrest in cancer cell lines 
Cells are expected to arrest in G2 if the CDK1/
Cyclin B1 complex is inactive. However, PPP treatment 
yielded increased CDK1 activity. One possible explanation 
would be that the cell cycle arrest corresponded to 
accumulation of mitotic cells having high CDK1/Cyclin 
B1 activity. To investigate this hypothesis, arrested cells 
were analyzed by flow cytometry using the mitosis marker 
phosphorylated histone H3 (pH3). This confirmed that the 
cells were in fact accumulated in mitosis (Fig. 4A). In 
PPP-treated HepG2 cells the percentage of pH3-positive 
cells increased after PPP addition to 4- and 3-fold at 8 
and 24h, respectively. Similar effects were observed in 
Hep3B and A549 cells (Fig. 4A). The potential effect of 
IGF-1R on the mitotic arrest was assessed in a knock-
down experiment in Hep3B cells using siRNA, showing 
that IGF-1R depletion did not affect the PPP-induced 
accumulation of cells in mitosis (Fig. 4B).
Time-lapse video microscopy showed that many 
cells rounded up after PPP addition and contained pH3-
positive condensed DNA, without signs of chromosome 
Figure 3: PPP induced an early increase in Cyclin B1, phosphorylation of CDK1pT161 and de-phosphorylation of 
CDK1Y15. HepG2 cells and nHeps were incubated with vehicle or with PPP for the indicated time points. Cell lysates were separated on 
12% Bis-Tris SDS-PAGE and protein levels were detected by Western blot (15 µg protein loaded per lane). GAPDH served as a loading 
control (A, B). The amount of Cyclin B1 in complex with CDK1 was detected by immunoprecipitation of CDK1 followed by Western 
blot using a Cyclin B1-specific antibody (C). Densitometric analysis of the Western blots in (A) normalized to GAPDH are represented as 
fold-difference between the band intensities of PPP-treated cells (red) compared to vehicle-treated cells (black) (D). mRNA expression of 
cyclin B1 determined by quantitative real-time RT-PCR (TaqMan) at different time points after treatment of HepG2 cells with PPP (red) or 
with vehicle (DMSO) (black) normalized to GAPDH are represented as fold-difference (E). Data is presented as mean ± SD of duplicate or 
triplicate experiments, and considered significant (*) at p ≤ 0.05. nHep: normal hepatocytes, PPP: picropodophyllin. 
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congression, indicating that cells were arrested in pro-
metaphase (Fig. 4C). The mitotic entry/time spent 
in mitosis were followed for individual U2OS cells 
expressing GFP-Histone H2B. While control cells entered 
mitosis linearly, cells treated with PPP showed a minor 
delay in interphase (Suppl. movie 1, Fig. 4D). In contrast 
to control cells spending less than an hour in mitosis, 
mitotic progression was severely delayed immediately 
after the addition of PPP (Fig. 4D). This delay was 
pronounced also when PPP was added to cells already 
in mitosis (Suppl. movie 3). A fraction of PPP-treated 
cells eventually died, and the surviving fraction exhibited 
abnormal DNA content/polyploidy and enlarged nuclei, 
suggesting the involvement of mitotic catastrophe (Fig. 
S4A, B).
PPP arrested cells in pro-metaphase by preventing 
the formation of a bipolar spindle and it induced 
spindle collapse in metaphase cells
The molecular mechanism underlying the mitotic 
arrest by PPP was investigated by live imaging using 
the U2OS cell line expressing GFP-Histone H2B and 
mCherry-a-tubulin. Whereas centrosome separation 
occurred before visible chromosome condensation in 
control cells, centrosomes remained close together during 
mitotic entry after PPP addition and a bipolar spindle 
never formed, leading to pro-metaphase arrest (Fig. 5A, 
Suppl. movie 1). No effects on centrosome maturation 
or the kinetics of chromosome condensation during 
mitotic entry were observed (Fig. 5A). When cells with 
established bipolar mitotic spindle were treated with PPP, 
the spindle collapsed and chromosome congression was 
reverted, showing that PPP affects both mitotic spindle 
Figure 4: PPP induced mitotic arrest in pro-metaphase. FACS analysis of HepG2, Hep3B and A549 cell lines after 24 h treatment 
with PPP, stained with both the mitosis marker phospho-histone 3 (ph3) and PI. A histogram showing the percentages of HepG2 cells in 
M-phase after 8 and 24 h treatment with vehicle (black) or with PPP (red) represented as fold-difference (A). Hep3B cells were transiently 
transfected with either IGF-1R siRNA or scrambled siRNA (mock) for 48h, followed by FACS analysis of transfected cells with both ph3 
and PI staining (B). Dual immunofluorescence staining of ph3 (red) and tubulin (green) in Huh7 cells after treatment with PPP. The four 
stages of mitosis could be distinguished in the vehicle-treated cells (left panels), while the PPP-treated cells were arrested in pro-metaphase 
(C). Individual cell fate of U2OS cells expressing H2B-GFP was monitored by time-lapse video microscopy. Fate is depicted by horizontal 
lines. Each line represents a single cell with the length indicating time spent in mitosis. Cumulative mitotic entry is represented as the 
percentage of U2OS cells entering mitosis (y-axis) against time in hours (x-axis) for vehicle-treated cells (top panel) and PPP-treated 
cells (bottom panel). Arrows indicate the time point of PPP or DMSO addition (D). ph3: phospho-histone 3, PI: Propidium iodide, PPP: 
picropodophyllin.
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assembly and maintenance (Fig. 5B, Suppl. movie 3). 
Bipolar spindle assembly depends on Aurora A kinase 
and its downstream target polo-like kinase 1 (Plk1), 
suggesting that the activity of these proteins might have 
been affected by PPP treatment. This was studied using 
a FRET-based sensor that monitors Plk1 phosphorylation 
in living cells [30]. Whereas the addition of either PPP or 
the Plk1 inhibitor BI2536 caused arrest in pro-metaphase, 
only BI2536 decreased the inverted FRET-ratio in both 
G2 and mitosis. This indicated that PPP did not induce a 
mitotic arrest by the inhibition of Aurora A or Plk1 kinase 
activities (Fig. 5C, Suppl. movie 2).
Addition of PPP in metaphase led to a gradual 
decrease in spindle length that eventually resulted in 
bipolar spindle collapse (Fig. 6A, D, Suppl. movie 3). 
Centrosome separation and bipolar spindle assembly 
mechanistically depend on the motor protein kinesin-5 
(Eg5) [31]. However, Eg5 is not essential for maintenance 
of a bipolar spindle when cells are arrested in metaphase 
[22, 23]. Thus, although addition of the Eg5 inhibitor 
STLC before mitosis led to inhibition of centrosome 
separation and pro-metaphase arrest (data not shown), 
addition of STLC to cells that were arrested in metaphase 
by the proteasome inhibitor MG132 did not lead to a 
mitotic spindle collapse (Fig. 6A, D, Suppl. movie 3). In 
contrast, addition of PPP in metaphase led to a gradual 
decrease in spindle length that eventually resulted in 
bipolar spindle collapse, indicating that PPP does not 
function through inhibition of Eg5 (Fig. 6A, D, Suppl. 
movie 3). 
PPP interfered with microtubule dynamics 
The effects of PPP on cells arrested in metaphase by 
MG132 were compared with the effects of the microtubule 
destabilizer Nocodazole (NOC), and the Eg5 inhibitor 
STLC. Treatment with PPP or NOC led to a collapse of the 
mitotic spindle, whereas STLC did not have any detectable 
effect (Fig. 6A, D, Suppl. movie 3). Importantly, whereas 
mCherry-a-tubulin distribution remained constant after 
STLC or DMSO addition, the addition of either PPP or 
NOC in the same phase of cell division led to an increase 
in the pool of mCherry-a-tubulin outside of the spindle 
Figure 5: PPP interfered with mitotic spindle establishment and maintenance. PPP prevented centrosome separation and 
establishment of a bipolar spindle during mitotic entry (A). PPP or DMSO was added to U2OS cells stably expressing GFP-Histone H2B 
and mCherry-a-tubulin. Cells entering mitosis were followed with time-lapse microscopy. Images show maximum intensity projections of 
Z-stacks with 1µM spacing. Minutes from addition of PPP are indicated. PPP disrupted mitotic spindle integrity and mitotic progression. 
Similar to (A) but following cells where a mitotic spindle was already established at the time of drug addition (B). PPP did not affect Plk1 
activity (C). U2OS cells stably expressing a FRET-based probe to monitor Plk1 target phosphorylation were followed through mitosis. 
Images show false-colored inverted FRET ratio according to the displayed scale bar. The incubation time following addition of drug is 
indicated in hours. H2B: GFP-Histone H2B, Tub: mCherry-a-tubulin, Plk1: polo-like kinase 1, PPP: picropodophyllin.
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(Fig. 6B, Suppl. movie 3), and to a decrease in the amount 
of mCherry-a-tubulin associated with the spindle (Fig. 
6C, Suppl. movie 3). This phenotype was evident in all 26 
PPP-treated cells studied in the experiment.
The potential effects of PPP on microtubule 
dynamics during interphase were compared with the 
effects of the microtubule depolymerizer colchicine. The 
number of cells without visible microtubules was counted 
using immunofluorescence microscopy. A substantial 
effect was observed 8 h after colchicine addition, whereas 
PPP had minor effects (Fig. 7A, B). The effect seen with 
PPP at 12 h did reach statistical significance compared 
to the starting value for PPP treated cells, but remained 
below the starting value for the colchicine treated cells. 
Several experiments were performed to investigate 
whether PPP might bind directly to microtubules. We 
measured displacement of tritiated colchicine, PPP, or 
PPT (Fig. S5). Colchicine and PPT competed for binding 
to b-tubulin, whereas PPP did not displace colchicine, 
despite that a concentration as high as 50 µM was used. 
For PPT, this displacement resembled the pattern for cold 
colchicine (Fig. S5). In a final competition experiment, no 
binding curve for tritiated PPP binding to b-tubulin could 
be established. The weak signal could not be blocked with 
cold PPP (or cold PPT) confirming that this was not a 
result from specific binding. Thus, PPP mediates a mitotic 
arrest by interfering with microtubule dynamics, without 
binding to b-tubulin. 
DISCUSSION 
In this study we confirmed that the PPP-induced 
G2/M arrest is independent of IGF-1R because it occurred 
in igf1r-/- (R-) MEFs and after IGF-1R downregulation 
using siRNA in cancer cell lines. The G2/M arrest also 
occurred in cancer xenografts in vivo after PPP treatment. 
Detailed studies showed that the PPP-induced G2/M 
arrest paralleled the activation of Cyclin B1/CDK1 activity 
in vitro and in vivo, indicating that cells accumulated in 
mitosis. This was confirmed by phospho-histone H3 
Figure 6: PPP addition in metaphase led to spindle collapse, increased levels of diffusible mCherry-a-tubulin, and 
decreased levels of spindle-associated mCherry-a-tubulin. U2OS cells stably expressing GFP-Histone H2B (H2B) and mCherry-
a-tubulin (Tub) were blocked in metaphase by treatment with 20 µM MG132 for 1.5h, followed by time-lapse microscopy. After acquisition 
of the first image, 0.5 μM PPP, 25 ng/mL Nocodazole (NOC), 40 µM S-Trityl-L-Cysteine (STLC), or DMSO were added (A). Images 
show maximum intensity projections of mCherry-a-tubulin, GFP-Histone H2B, and the merged channels (Merge). Time (minutes) from 
addition is indicated above images. Top graph shows normalized quantifications on average mCherry fluorescence in area of the cell 
where no visible spindle structure is present, indicating the free pool of diffusible mCherry-a-tubulin (B). Middle graph shows normalized 
quantifications of maximum mCherry intensity in cells, indicating accumulation of mCherry-a-tubulin in mitotic spindle (C). Lower graph 
shows distance between centrosomes (D). All values are averages of at least 7 cells per condition. 
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positive staining of the growth arrested tumor cells. 
Therefore, the “G2/M” arrest observed in the propidium 
iodide-based FACS analyses in this and in previous reports 
is in fact a mitotic arrest. 
Real-time imaging of a U2OS cell line stably 
expressing GFP-Histone H2B and mCherry-a-tubulin 
confirmed that the cells were arrested in mitosis. Addition 
of PPP before mitotic entry inhibited centrosome 
separation and the formation of a bipolar mitotic spindle, 
leading to pro-metaphase arrest. PPP addition to cells 
already in mitosis led to a collapse of the mitotic spindle. 
Changes in mitotic spindle structure occurred within 10 
minutes after addition of PPP, indicating that PPP acts 
directly on a regulator of the mitotic spindle and not 
through effects on transcription or protein synthesis. 
The effect after addition of PPP during metaphase was 
shown to be similar to the effect seen after addition of the 
microtubule destabilizer nocodazole (NOC). In both cases 
collapse of the mitotic spindle was observed, associated 
with decrease in the amount of tubulin associated with 
the spindle and concomitant increase in the tubulin pool 
outside of the spindle. 
Cells cannot remain permanently arrested in 
pro-metaphase [32]. In the present study some of the 
mitotically arrested cells were found to die in mitosis and 
the remaining cells exhibited enlarged polyploid nuclei, a 
scenario similar to that described for mitotic catastrophe 
[33, 34]. Indeed, cells may survive mitotic arrest by 
exiting mitosis without completing cell division (mitotic 
slippage) to become multinucleated [34]. It has been 
proposed that the inhibition of transcription during mitotic 
arrest and its restoration after mitotic slippage explain the 
different scenarios of cell fate determination after mitotic 
arrest [34]. Inhibition of transcription during mitotic arrest 
mediated by PPP might explain the reduced levels of the 
major microtubule-associated protein Tau in PPP-treated 
A549 xenografts observed in the present study (data 
not shown). This notion is corroborated by the fact that 
reduction in Tau was not observed in normal lung tissue 
from the same mice, because lung tissue is quiescent. 
Furthermore, mitotic arrest occurred within minutes in the 
A549 cell line but Tau reduction was observed in the same 
cell line after 16 h. 
It was recently reported that exposure to PPP, 
at a very high concentration (i.e. 10 µM), has an effect 
on microtubules, leading to blurry tubular staining in 
micrographs taken after 24 or 48 hours [35]. The authors 
suggested that this effect is due to PPP binding weakly to 
b-tubulin at the same location as colchicine and the PPP 
diastereomer podophyllotoxin (PPT). However, binding 
competition studies using tritiated colchicine as the tracer 
have previously shown that PPP does not compete with 
colchicine, in contrast to PPT [36]. This experiment was 
extended in the current study, measuring displacement 
of tritiated colchicine, PPP, or PPT, by the unlabeled 
compounds. In agreement with previous data colchicine 
and PPT competed for binding to b-tubulin, whereas PPP 
did not. Furthermore, in the third part of the experiment 
no specific binding of tritiated PPP to b-tubulin could be 
established.
Centrosome separation and the formation of a 
bipolar mitotic spindle requires controlled changes in 
microtubule dynamics [37]. These processes depend on 
the activities of Aurora A kinase and its downstream target 
Plk1, which has prompted interest in their function as anti-
cancer targets [38]. However, the present study showed 
that Plk1 activity remained high after addition of PPP, 
indicating that PPP does not function through Plk1. The 
study also showed that PPP does not function through 
inhibition of the motor protein Eg5, needed for centrosome 
separation [31].
To investigate whether PPP could induce rapid 
Figure 7: Effect of PPP on microtubule organization in interphase. Hep3B and Huh7 cells were treated with either 0.5 µM 
PPP or 0.05 µM colchicine, followed by visualization of b-tubulin by immunofluorescence using an Alexa-conjugated b-tubulin binding 
antibody. After 8 h treatment microtubule organization appeared intact in vehicle-treated control cells (DMSO) (left panels) and in PPP-
treated cells (middle panels). Microtubule disorganization was observed following treatment with 0.05 µM colchicine (right panels) (A). 
The fraction of cells with disorganized microtubules at different time points were calculated and depicted in a histogram (B). Data represent 
mean ± SD, n=3, and considered significant at p ≤ 0.05. (*) both between colchicine- and PPP-treated cells and between PPP- and vehicle-
treated cells.
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effects on the microtubule system in other cancer cells 
in interphase immunofluorescence microscopy was used, 
and we could only detect weak depolymerizing effects in 
comparison to a very low dose of the microtubule inhibitor 
colchicine that induced drastic depolymerisation of the 
microtubule system. This together with previous results 
indicated that PPP has only a very weak microtubule 
inhibitor activity in this experimental setting. 
A number of microtubule inhibitors are presently 
used in clinical oncology. They have severe adverse 
effects including bone marrow depression, gastrointestinal 
and neurological disturbances [39]. In contrast, PPP 
has been shown to be well tolerated in patients despite 
administration twice daily for weeks and months, with 
reversible neutropenia as the only dose-related and 
dose-limiting toxicity [11]. The chief limitation of 
microtubule-targeted agents is the high rate of neuropathy 
induced by these agents [40]. The gastrointestinal side 
effects of microtubule-inhibiting drugs, i.e. diarrhea, 
melena and paralytic ileus, are probably explained by 
the high proliferative activity in the intestinal mucosa. 
No drug-related, clinically important gastrointestinal 
or neurological events have been reported after oral 
administration of PPP in the clinic [11, 12]. These early 
clinical data indicate that PPP does not show the typical 
side effects of general microtubule inhibitors thus 
suggesting that PPP might affect microtubule dynamics 
in a different manner than currently available drugs. 
Microtubule dynamics is spatially highly regulated 
in mitosis [26, 37], and it is possible that PPP affects 
proteins that regulate this process. Furthermore, binding 
to polymerized or modified forms of b-tubulin found in the 
cellular context cannot be ruled out.
In the present study PPP treatment resulted in 
prominent CDK1 activation with increased levels of 
Cyclin B1 protein and mRNA, increased Cyclin B1 in 
complex with CDK1, and CDK1Thr161 phosphorylation in 
cancer cell lines or tumors. PPP did not seem to directly 
target CDK1 and the activation of CDK1 by PPP in cell 
lines occurred the earliest after 2-4 h incubation, while 
the interference with tubulin and spindle formation 
occurred after minutes of PPP addition. Therefore, the 
CDK1 activation induced by PPP may be a consequence 
of its effect on mitosis. Other compounds affecting the 
microtubules have been shown to induce similar effects 
[41, 42]. PPP did not induce G2/M arrest or CDK1 
activation in normal human hepatocytes (nHeps) or in 
normal lung tissue from xenografted mice. This may 
be explained by the fact that nHeps and cells in lung 
tissue are quiescent and do not enter mitosis [43]. In 
agreement, we further investigated the effect of PPP on the 
proliferating normal human fibroblast cell line GM2808. 
We observed a 1.5-fold increase in the percentage of cells 
in the G2/M phase of the cell cycle after 24 h treatment 
with the same dose of PPP (data not shown). This supports 
the fact that PPP selectively eliminates proliferating cells, 
which is relevant for cancer therapy, aiming to target the 
proliferating cancer cell that invades and metastasizes 
[44]. 
In the present study PPP induced statistically 
significant apoptosis only in HepG2 and MCF-7 cell lines 
and not in Hep3B or Huh7 cells. This was accompanied 
with a reduction in Mcl-1. The reduced Mcl-1 levels 
may be due to its degradation by CDK1 phosphorylation 
because CDK1 knockdown using siRNA rescued these 
effects. This is in agreement with previous results [24]. 
HepG2 and MCF-7 cell lines have wild type p53, whereas 
Hep3B lacks p53 and Huh7 harbors mutated p53 [45]. 
During PPP-induced mitotic arrest, mitotic inhibition of 
transcription may cause the level of Mdm2 mRNA and 
other short-lived mRNAs to decrease rapidly. Subsequent 
loss of Mdm2 results in stabilization of p53 in cell lines 
having wild type p53. Furthermore, due to more long-lived 
p53 mRNA synthesis may continue for some time after a 
block in transcription, causing p53-dependent apoptosis 
(reviewed in [34]). A recent study supports that the p53-
status may explain the sensitivity to PPP [46].
In conclusion, our results demonstrate a novel 
mechanism of action of the anticancer agent PPP, 
interfering with microtubule dynamics and leading to 
mitotic arrest. The effect is observed within minutes, 
and is not caused by direct effects of PPP on b-tubulin, 
CyclinB/CDK1, Aurora A, Plk1, Eg5. We suggest that the 
microtubule effect is mechanistically separate from the 
widely reported effects on IGF-1R pathway. It is likely 
that the ability to cause mitotic arrest of tumor cells is an 
essential component of the anti-tumor efficacy of PPP, 
since this may lead to mitotic catastrophe and subsequent 
cell death. 
MATERIALS AND METHODS
Cell lines and reagents
HepG2 cell line (DSMZ, Braunschweig, Germany) 
was cultured in RPMI 1640 (Gibco, Paisley, UK) 
with 10% fetal bovine serum (FBS; Hyclone, Logan, 
UT), whereas Hep3B (ATCC, Manassas, VA) and 
Huh7 (Professor M. Ingelman-Sundberg, Karolinska 
Institutet, Stockholm, Sweden) were cultured in DMEM 
(Gibco) with 10% FBS. As a normal counterpart to 
these hepatoma cell lines, human hepatocytes (nHep) 
(Lonza, Basel, Switzerland) were used and maintained 
in hepatocyte basal medium supplemented with the 
HCM™ bullet kit®  (Lonza). A549, MCF-7 (Professor K. 
Wiman, Karolinska Institutet), igf1r-/- mouse embryonic 
fibroblasts (R-MEF), IGF-1R-overexpressing (R+MEF) 
(Professor R. Baserga, Thomas Jefferson University, 
PA) and U2OS expressing green fluorescent protein 
(GFP)-Histone H2B (J. Raaijmakers and R. Medema, 
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Dutch Cancer Institute, the Netherlands) were cultured 
in DMEM with 10% or 6% FBS (U2OS). All cell lines 
were maintained in complete medium with penicillin 
(100 units/ml), streptomycin (50µg/ml) (Hyclone, Logan, 
UT) at 37°C in a humidified atmosphere containing 5% 
CO2 and confirmed authentic using Short Tandem Repeat 
kit AmpFSTR identifier (Applied Biosystems, Foster 
City, CA). PPP and picropodophyllotoxin (PPT) were 
synthesized as described [3], and similar to colchicine, 
nocodazole, MG-132 (Sigma, St Louis, MO), S-Trityl-L-
Cysteine (STLC) (Tocris Bioscience, Ellisville, MO) and 
BI 2536 (Selleckchem, Houston, TX) were dissolved in 
dimethylsulphoxide (DMSO).
A549 xenograft model
A549 cells (2x106) in sterile phosphate-buffered 
saline (PBS) were injected subcutaneously in the flanks 
of 5-6 week-old immunodeficient, female nu/nu Balb/c 
mice. After 50 days, mice were treated using an oral 
gavage with either PPP (40 mg/kg) or vehicle (7.5 mL/kg) 
at 0, 12 and 24 h with daily monitoring of tumor growth 
using a vernier caliper. At 3 h after the last treatment, 
animals were sacrificed, tumor weights and volumes 
determined and tumor and lung tissues were collected, 
snap-frozen in liquid nitrogen and stored at -80°C. Animal 
experiments were performed by ProQinase (Freiburg, 
Germany) according to the guidelines of the Federation 
for Laboratory Animal Science Associations, EU.
Analysis of cell growth, cell cycle distribution and 
apoptosis
Cell viability was determined with the alamarBlue® 
assay (Invitrogen) as described in [47]. Cell cycle phase 
distribution was analyzed by flow cytometry using 
propidium iodide (PI) as described in [14]. For M-phase 
quantification, cells were fixed with 70% ethanol, 
permeabilized using 0.25% TritonX-100, incubated 
with anti-phospho-histone H3 (pH3) antibody 06-570 
(Millipore, Temecula, CA) for 1 h at room temperature 
(RT), washed with PBS containing 1% bovine serum 
albumin (BSA) and incubated with goat anti-mouse Alexa 
Fluor 488-conjugated antibody A11029 (Invitrogen) and 
PI. Following analysis with flow cytometry, the data 
were processed with the Cell Quest software (Becton 
Dickinson, San Jose, CA) or ModFit Software (Verity 
Software, Topsham, ME). For the analysis of cell cycle 
phase distribution of cells from tumor and lung tissue 
of A549 xenografts, the formalin-protease method was 
adopted as described [48], followed by quantification 
using ModFit Software. Apoptosis was studied using 
Annexin V/PI method (Annexin V-FLUOS staining 
kit, Roche, Mannheim, Germany) according to the 
manufacturer’s protocol. Flow cytometric analysis was 
immediately performed using FACS Calibur.
siRNA knockdown of IGF-1R and CDK1
IGF-1R- and mock-siRNA (Thermo 
Fisher Scientific, Waltham, MA) were transfected 
into Hep3B cells at 40% confluence by adding 8 μL 
Dharmafect 4 (Invitrogen, Carlsbad, CA) and 40 nmol 
siRNA to 2 mL antibiotic-free medium. CDK1- and 
mock-siRNA (Qiagen, Hilden, Germany) were transfected 
into MCF-7 cells by adding 12 μL of oligofectamine 
(Invitrogen, Carlsbad, CA) and 10 nmol of siRNA to 2 
mL antibiotic-free medium. After 48 h (IGF-1R siRNA) 
or 72 h (CDK1 siRNA) the cells were washed with fresh 
medium and then treated with PPP or vehicle for an 
additional 24 h before analysis. The knockdown efficiency 
was 80-90% as assessed by Western blotting.
Western blotting
Cells were lysed in modified RIPA buffer (50 mM 
Tris pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 
0.25% sodium deoxycholate) containing protease 
(Roche) and phosphatase (Sigma) inhibitors. Lysates 
were centrifuged at 16,100 x g at 4ºC for 30 min and 
supernatants stored at -80ºC. Protein concentrations were 
determined using BCA (Pierce Biotechnology, Rockford, 
IL) and equal amounts of protein were resolved on 4-12% 
gradient- or 12% Bis-Tris SDS-PAGE gels (Invitrogen), 
transferred to nitrocellulose Hybond membranes 
(Amersham, Buckinghamshire, UK), blocked with 5% 
dry milk or BSA in 20 mM Tris base, 135 mM NaCl, 
0.1% Tween 20 (TBST) and blotted against rabbit anti-
caspase3 #9662, rabbit anti-CDK1pT161 #9114, rabbit anti-
CDK1pY15 #9111, mouse anti-Cyclin B1 #4135, and rabbit 
anti-Mcl-1 #5453 antibodies (Cell Signaling Technology, 
Beverly, MA) or rabbit anti-GAPDH sc-25778 antibody 
(Santa Cruz Biotechnology, Santa Cruz, CA) or mouse 
anti-PARP #556363 (Becton Dickinson) or rabbit anti-
CDK1 #PC25 antibody (Calbiochem, San Diego, CA). 
Membranes were routinely washed using TBST, and 
incubated with secondary anti-rabbit/mouse/goat IgG 
horseradish peroxidase-conjugated antibodies NA934, 
NA931 (Amersham) or 31402 (Pierce Biotechnology) 
followed by signal detection using enhanced luminescence 
Hyperfilm-ECL (Amersham) and quantification using 
imageJ. 
CDK1 kinase assay
Cells/tumor tissue were lysed in PBS pH 7.0 
containing 10% glycerol, 0.5 mM EDTA, 1 mM DTT, 
2 mM NaF, 0.2% Triton-X 100, protease/phosphatase 
inhibitors [47] and processed as described above. CDK1 
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was immunoprecipitated using mouse anti-CDK1 agarose-
conjugated antibody sc-54 (Santa Cruz Biotechnology) 
followed by washing and re-suspension in kinase buffer 
with 10 mM DTT and 20-50 µM unlabeled ATP. After 
addition of 1.5 g histone H1 (Roche) and 5-10 µCi γ-32P 
(Perkin Elmer, Rodgau, Germany), the samples were 
incubated for 30 min at 30˚C with termination by 4 x SDS-
PAGE sample buffer followed by electrophoresis on 12% 
polyacrylamide gel with final analysis/quantification by 
autoradiography/densitometry [47].
RNA isolation and real-time RT-PCR
Total RNA was isolated using the RNeasy kit 
(Qiagen) and stored at -80°C until use. The concentration 
and the quality of isolated RNA were determined 
using NanoDrop1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE). cDNA was generated 
from 2 µg of total RNA with Reverse Transcription Kit 
(Applied Biosystems) and the concentration determined as 
above. Real-time RT-PCR was carried out (10 min 95ºC, 
40 cycles 15 s 95ºC, 1 min 60ºC) using the ABI 7500 
probes for cyclin B1 (Hs00259126_m1) and GAPDH 
(Hs02758991_g1), each having the fluorochrome FAM 
conjugated at the 5’ end (Applied Biosystems). 
Immunofluorescence analysis of tubulin and 
phosphohistone H3 (pH3)
The cells, seeded on coverslips, were fixed in 4% 
buffered paraformaldehyde solution, permeabilised using 
0.1% TritonX-100, incubated overnight with rabbit anti-
pH3 antibody 04-817 (Millipore), washed with PBS 
containing 5 mM EGTA and incubated with goat anti-
rabbit Alexa Fluor 594-conjugated antibody A11012 
(Invitrogen) for 1 h at RT. For subsequent staining of 
tubulin, cells were washed with PBS-EGTA, incubated 
with mouse anti-tubulin antibody T5168 (Sigma) for 
1 h at RT, washed with PBS-EGTA and incubated with 
goat anti-mouse Alexa Fluor 488-conjugated antibody 
A11029 (Invitrogen). For counterstaining of cell 
nuclei, the coverslips were mounted using Vectashield 
mounting medium containing DAPI (Vector Laboratories, 
Burlingame, CA). Cells were examined using an Axioplan 
2 fluorescence microscope (Zeiss, Jena, Germany).
Live cell imaging
Time-lapse video microscopy was performed 
at 37oC with 5% CO2 on an inverted Leica DMI6000 
microscope using NA 0.4 and 0.85 dry objectives. Images 
were acquired with a Photometrics Evolve 512 EM-
CCD camera using Leica Application Suite software and 
analyzed by using ImageJ. For images of U2OS cells 
expressing both mCherry-a-tubulin and GFP-Histone 
H2B, Z-stacks with a spacing of 1 µm were acquired 
and are represented as maximum intensity projections. 
mCherry-a-tubulin association to the mitotic spindle was 
measured by taking the maximum mCherry intensity of the 
cell, whereas the diffusible pool of mCherry-a-tubulin was 
assessed by measuring the average mCherry fluorescence 
in an area of the cell where no visible spindle structure is 
present. Inverted fluorescence resonance energy transfer 
(FRET) ratios of a Plk1-responsive probe [30] were 
monitored and analyzed as described [49].
Tubulin-binding assay
Binding of PPP and PPT (both from the Biovitrum 
compound collection) and colchicine (Sigma C-9754) 
were performed using Colchicine site competitive assay 
kit Cytodynamix Screen 15 (Cytoskeleton, CDS15), 
according to the manufacturer’s instruction. In separate 
experiments [3H]-Colchicine (American Radiolabeled 
Chemicals, ART-722), [3H]-PPP (Biovitrum) or [3H]-
PPT (Biovitrum) were used as tracers, having specific 
activities of approximately 3145, 670, and 670 GBq/
mmol, respectively. The concentration of [3H]-colchicine 
in the assay was 53 nM, and the concentration of [3H]-
PPP or [3H]-PPT was 4-fold higher, due to lower specific 
activity, keeping within the limit of the kit procedure as 
stated by the manufacturer. Compound stock solutions 
were 10mM in DMSO, and serial dilutions 1:3 were 
made in DMSO prior to transfer to the assay plate. Top 
concentration of compound dilution in the assay was 42 
µM. Serial dilutions were made in duplicates. Briefly, 10 
µL of compound dilution and 10 µL of tracer dilution were 
incubated with 180 µL of tubulin-biotin SPA-beads for 45 
minutes at 37 ˚C after a short initial shake. Readings were 
done using a 1450 MicroBeta Trilux 32 BI. Data were 
analysed using Xlfit 4 parametric linear regression model 
205.
Statistical analysis
Statistical significance was defined as p ≤ 0.05 based 
on two-sided Student’s t-test. 
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